We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Although infrequent, high use of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Increasing exposure to short-acting beta ...

I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...

In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...

Overuse of rescue medication among asthma patients is associated with increased exacerbations and higher total and asthma-related healthcare costs. Objective: To assess whether increased short-acting ...

In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...

Beta-2 agonists are bronchodilators commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Although beta-2 agonists have been associated with a reduced risk of ...

Children with mild asthma at low risk for severe exacerbations may not need daily or as-needed ICS, as GINA guidelines recommend.

Recently, the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older.

Perforomist is a solution formulation of the long-acting beta 2-agonist formoterol fumarate, which is administered by inhalation via nebulization. It acts as a bronchodilator by stimulating beta 2 ...